The new version of the company’s product enables validation of larger microRNA signatures rapidly and inexpensively.
FirePlex miRSelect is a sensitive method for multiplexed detection of microRNAs across a broad range of sample types.
The product waves off the purchase of dedicated equipment or lengthy sample preparation protocols.
The new Firefly platform allows for speedy and cost-effective testing of large numbers of samples across more microRNA targets than ever before.
MiRSelect, in addition to validation studies, is also used to a wide array of research areas, including biomarker discovery, translational research, developmental biology and model organism research.
Firefly BioWorks co-founder and chief executive officer Dr. Davide Marini said the expanded capability of miRSelect will resonate with researchers looking to validate early discovery studies on statistically significant numbers of samples.
"This latest version of miRSelect is an important step toward our mission of enabling all scientists to engage those ambitious explorations that are considered too expensive, labor intensive or time consuming with existing technology," Marini added.